Regeneron Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Leonard S. Schleifer
- Full Time Employees
- 15,410
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 777 Old Saw Mill River Road Tarrytown NY United States of America 10591-6707
- IPO Date
- Apr 2, 1991
- CIK
- 0000872589
- Website
- regeneron.com
- Similar Companies
- Business
- Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases including eye disorders, allergic and inflammatory conditions, cancer, cardiovascular and metabolic diseases, neurological disorders, hematologic conditions, infectious diseases and rare diseases. Founded in 1988 and headquartered in Tarrytown, New York, the company operates globally with facilities in the United States and clinical trials underway in more than 50 countries; it employs proprietary technologies such as VelociSuite for fully human antibodies and bispecifics, Trap fusion proteins and the Regeneron Genetics Center for data-powered insights. Its marketed products include EYLEA (aflibercept) for retinal diseases such as wet age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion; Dupixent (dupilumab, in collaboration with Sanofi) for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps and other allergic conditions; Praluent (alirocumab) for hypercholesterolemia; Kevzara (sarilumab, with Sanofi) for rheumatoid arthritis; Libtayo (cemiplimab) for cutaneous squamous cell carcinoma and other cancers; ARCALYST (rilonacept) for autoinflammatory diseases; ZALTRAP (ziv-aflibercept) for metastatic colorectal cancer; Inmazeb for Ebola virus infection; Veopoz (pozelimab) for CHAPLE disease; as well as investigational candidates across oncology, hematology, immunology and neurology. In recent developments, Regeneron formed Regeneron Cell Medicines in 2024 through an agreement acquiring 2seventy bio's immune cell therapy pipeline, discovery and manufacturing capabilities along with approximately 150 employees in Cambridge, Massachusetts, and Seattle, Washington; announced a $3 billion-plus, 10-year manufacturing agreement with FUJIFILM Diosynth Biotechnologies in 2025 to nearly double U.S. large-scale capacity at the Holly Springs, North Carolina facility; launched a $500 million venture capital fund in 2024 focused on biotech investments; entered a collaboration with Tessera Therapeutics in December 2025 to co-develop TSRA-196, a gene-editing therapy for alpha-1 antitrypsin deficiency, with Tessera receiving $150 million upfront and up to $125 million in milestones; secured FDA approval for EYLEA HD in retinal vein occlusion with expanded dosing in 2025; and won a $406.8 million antitrust judgment against Amgen in May 2025 over Praluent market exclusion. The company continues to advance its pipeline with positive late-stage data in immunology, allergy, neurology and rare diseases, while expanding R&D investments and domestic manufacturing to support growth.
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
REGN EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
REGN Deadline Alert: SueWallSt Reminds Regeneron Pharmaceuticals (REGN) Investors of Securities Class Action Deadline on September 14, 2026
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP
BlackRock Inc. Makes New $5.68 Billion Investment in Regeneron Pharmaceuticals, Inc. $REGN
Regeneron Pharmaceuticals, Inc. Notice of September 14, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline
REGN CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
REGN UPCOMING DEADLINE: Levi & Korsinsky Alerts Regeneron Pharmaceuticals, Inc. Stockholders of Securities Class Action - Contact the Firm
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Focus Partners Advisor Solutions LLC Invests $1.35 Million in Regeneron Pharmaceuticals, Inc. $REGN
AMG National Trust Bank Makes New $1.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
2 GLP-1 Stocks That Could Double Your Money by 2031
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit - Hagens Berman
The Gross Law Firm Reminds Regeneron Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN